专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230140653A1 NONINVASIVE MOLECULAR CLOCK FOR FETAL DEVELOPMENT PREDICTS GESTATIONAL AGE AND PRETERM DELIVERY 有权
公开(公告)号：US20230140653A1
公开(公告)日：2023-05-04
申请号：US16758844
申请日：2018-10-23
申请人： Chan Zuckerberg Biohub, Inc. , The Board of Trustees of the Leland Stanford Junior University , Statens Serum Institut
发明人： Mira N. Moufarrej , Thuy T. M. Ngo , Joan Camunas-Soler , Mads Melbye , Stephen R. Quake
IPC分类号： G16B20/00 , C12Q1/6883 , G16B40/20 , G16H50/20
摘要： The invention is directed to methods of predicting gestational age of a fetus. The invention is also directed to methods of identifying woman is risk for preterm delivery. In some aspects, the methods include quantitating one or more placental or fetal-tissue specific genes in a biological sample from the woman.

2. 发明申请

US20210398682A1 Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof 有权
公开(公告)号：US20210398682A1
公开(公告)日：2021-12-23
申请号：US17207541
申请日：2021-03-19
申请人： The Board of Trustees of the Leland Stanford Junior University , Statens Serum Institut
发明人： Liang Liang , Jijuan Gu Urban , Mads Melbye , Michael P. Snyder
IPC分类号： G16H50/30 , G16H50/20 , G16H10/60
摘要： Methods to compute gestational age and gestational health and applications thereof are described. Generally, systems utilize analyte measurements to determine a gestational age and gestational health, which can be used as a basis to perform interventions and treat individuals.

3. 发明申请

US20190099478A1 Vaccines against Chlamydia sp. 审中-公开
公开(公告)号：US20190099478A1
公开(公告)日：2019-04-04
申请号：US15956731
申请日：2018-04-18
申请人： Statens Serum Institut
发明人： Frank Follmann , Ida Kosenkrands , Anja Olsen , Peter Andersen
IPC分类号： A61K39/118 , C07K14/295 , A61K39/00
摘要： The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

4. 发明授权

US10004793B2 M.tuberculosis vaccines 有权
公开(公告)号：US10004793B2
公开(公告)日：2018-06-26
申请号：US15306239
申请日：2015-04-09
申请人： Statens Serum Institut
发明人： Claus Aagaard , Ida Rosenkrands , Truc Thi Kim Thanh Hoang , Peter Lawaetz Andersen
IPC分类号： A61K39/04 , C07K14/35 , A61K39/39 , A61K39/00
CPC分类号： A61K39/04 , A61K39/39 , A61K2039/5254 , A61K2039/55555 , A61K2039/575 , A61K2039/70 , C07K14/35 , C07K2319/00
摘要： The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant M. tuberculosis (MTB) antigens.

5. 发明授权

US09410960B2 Method of diagnosing galactosemia in neonatal screening 有权
标题翻译：新生儿筛查中半乳糖血症诊断方法
公开(公告)号：US09410960B2
公开(公告)日：2016-08-09
申请号：US14443997
申请日：2013-11-28
申请人： Statens Serum Institut
发明人： Arieh Sierra Cohen
IPC分类号： C12Q1/00 , G01N33/66 , C12Q1/54 , C12Q1/68
CPC分类号： G01N33/66 , C12Q1/00 , C12Q1/54 , C12Q1/6827 , C12Q1/6883 , G01N2400/00 , G01N2800/042 , G01N2800/385 , G01N2800/50
摘要： A method of diagnosing galactosemia in blood samples from neonates by determining GAL-1-P concentrations before 5-7 days of life is disclosed. The removal of interfering compounds allows a more specific and therefore more accurate determination of GAL-IP levels in newborn screening for galactosemia using mass spectrometry. This is of major importance when investigating samples from children that have not yet achieved a steady state of GAL-IP (i.e. before 5-7 day of life).
摘要翻译：公开了通过在生命5-7天之前测定GAL-1-P浓度来诊断来自新生儿血液样品中的半乳糖血症的方法。干扰化合物的去除可以使用质谱法更准确地测定新生儿筛查半乳糖血症中的GAL-IP水平。在调查尚未达到GAL-IP稳定状态的儿童的样本（即5-7天之前）时，这是非常重要的。

6. 发明申请

US20130095132A1 TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE 有权
标题翻译：包含在感染相关期间表达的抗原的管炎疫苗
公开(公告)号：US20130095132A1
公开(公告)日：2013-04-18
申请号：US13623733
申请日：2012-09-20
申请人： STATENS SERUM INSTITUT
发明人： Claus Aagaard , Carina Vingsbo-Lundberg , Peter Andersen
IPC分类号： C07K19/00
CPC分类号： C07K19/00 , A61K39/00 , A61K39/04 , C07K14/35 , C07K2319/00
摘要： The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
摘要翻译：本发明涉及用于预防，增强或治疗由结核分枝杆菌菌种（M.tuberculosis，M.Bovis，M. africanum，M.Microti）引起的感染的免疫原性组合物，疫苗或药物组合物。免疫原性组合物，疫苗或药物组合物包含融合多肽，其包含来自结核分枝杆菌的一种或多种饥饿抗原，融合多肽的单位是结核分枝杆菌抗原。此外，本发明涉及包含与BCG同时给予的融合多肽序列或本发明的核酸序列的疫苗或与BCG混合或在用于制备所述免疫原性组合物的不同位点或途径单独施用的疫苗的应用，疫苗或药物组合物。

7. 发明授权

US10925954B2 Vaccines against Chlamydia sp 有权
公开(公告)号：US10925954B2
公开(公告)日：2021-02-23
申请号：US15956731
申请日：2018-04-18
申请人： Statens Serum Institut
发明人： Frank Follmann , Ida Rosenkrands , Anja Olsen , Peter Andersen
IPC分类号： A61K39/118 , C07K14/295 , A61K39/00
摘要： The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

8. 发明授权

US10786579B2 Skin testing for tuberculosis in immunocompromised persons 有权
公开(公告)号：US10786579B2
公开(公告)日：2020-09-29
申请号：US15775673
申请日：2016-11-15
申请人： Statens Serum Institut
发明人： Henrik Aggerbeck , Peter Lawætz Andersen , Morten Ruhwald
IPC分类号： A61K39/04 , A61K39/02 , G01N33/554 , A61K49/00 , A61K9/00 , A61K39/09
摘要： Disclosed herein is the use of Mycobacterium tuberculosis antigens for use in in vivo determination of the presence of Mtb infection in immunocompromised persons or persons co-infected with HIV and the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtb infection infection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.

9. 发明申请

US20150293111A1 METHOD OF DIAGNOSING GALACTOSEMIA IN NEONATAL SCREENING 审中-公开
标题翻译：在隐性筛选中诊断胶质糖的方法
公开(公告)号：US20150293111A1
公开(公告)日：2015-10-15
申请号：US14443997
申请日：2013-11-28
申请人： Statens Serum Institut
发明人： Arieh Sierra COHEN
IPC分类号： G01N33/66
CPC分类号： G01N33/66 , C12Q1/00 , C12Q1/54 , C12Q1/6827 , C12Q1/6883 , G01N2400/00 , G01N2800/042 , G01N2800/385 , G01N2800/50
摘要： A method of diagnosing galactosemia in blood samples from neonates by determining GAL-1-P concentrations before 5-7 days of life is disclosed. The removal of interfering compounds allows a more specific and therefore more accurate determination of GAL-IP levels in newborn screening for galactosermia using mass spectrometry. This is of major importance when investigating samples from children that have not yet achieved a steady state of GAL-IP (i.e. before 5-7 day of life).
摘要翻译：公开了通过在生命5-7天之前测定GAL-1-P浓度来诊断来自新生儿血液样品中的半乳糖血症的方法。清除干扰化合物可以使用质谱法更准确地测定新生儿筛查半乳糖的GAL-IP水平。在调查尚未达到GAL-IP稳定状态的儿童的样本（即5-7天之前）时，这是非常重要的。

10. 发明申请

US20140205656A1 MODIFIED CATIONIC LIPOSOME ADJUVANTS 审中-公开
标题翻译：改性阳离子脂质体
公开(公告)号：US20140205656A1
公开(公告)日：2014-07-24
申请号：US14162511
申请日：2014-01-23
申请人： Statens Serum Institut
发明人： Dennis Christensen , Karen Smith Korsholm , Else Marie Agger , Peter Andersen
IPC分类号： A61K9/127 , A61K39/12 , A61K39/015 , A61K39/145 , A61K39/04
CPC分类号： A61K9/127 , A61K9/1272 , A61K39/015 , A61K39/04 , A61K39/118 , A61K39/12 , A61K39/145 , A61K2039/55555 , Y02A50/412
摘要： The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of antibodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CDS response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer.
摘要翻译：本发明涉及疫苗与包含阳离子脂质体的佐剂的疫苗，其中中性脂质已经引入脂质体中以改变凝胶 - 液相转变，从而改变IgG亚型应答并增强脂质体佐剂的CD8应答。该技术可用于增加IgG2抗体的产生。已经显示这种亚型抗体（对应于人类中的IgG3的小鼠中的IgG2）选择性地与先天免疫细胞表面上的Fc激活受体结合，导致增强的促炎反应，从而更高效的免疫应答，并具有较高的保护水平动物模型例如疟疾和衣原体。选择性地引起更高水平的IgG2抗体的佐剂的使用将改善疫苗的效果，例如，针对细胞内感染。此外，该技术可用于诱导CD8应答，其已被报道以改善疫苗对例如抗体的作用。已显示HPV，HIV，流感和癌症选择性地与先天免疫细胞表面上的Fc激活受体结合，导致增强的促炎反应，从而在例如动物模型中具有较高保护水平的更有效的免疫应答。疟疾和衣原体。选择性地引起更高水平的IgG2抗体的佐剂的使用将改善疫苗的效果，例如，针对细胞内感染。此外，该技术可以用于诱导CDS反应，其已经被报道以改善疫苗对抗体的作用。 HPV，HIV，流感和癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式